(Alliance News) - Barkby Group PLC on Monday said VivoPlex Group Ltd has obtained UK regulator approval to start the first clinical feasibility study of its uterine sensor system.
The wireless and battery-free system measures the pH, temperature, and dissolved oxygen level in the uterus for a period of up to seven days. This is intended to aid clinicians in optimising and personalising fertility treatments with the goal of improving success rates from in-vitro fertilisation.
The goal of the study is to obtain key clinical data to support European approval of the system, the first VivoPlex product and part of a range of reproductive health biosensors in development.
Study approval, Barkby said, marks "an important milestone for VivoPlex in the path towards commercialisation of its intra-uterine sensing system."
The study will start once clinical capacity is available following the Covid-19 pandemic.
Barkby Executive Chair Charles Dickson said: "VivoPlex aims to transform fertility treatment for millions of people and I am delighted that it is one step closer to realising that aim, having received regulatory approval for its clinical feasibility study. We are very excited by the business's potential to become a significant disruptor in the human fertility sector."
Shares in Barkby were untraded on Monday, having last closed at 23.25 pence.
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
